This Notice of Special Interest (NOSI) is issued by the National Institute of Neurological Disorders and Stroke (NINDS) to outline NINDS priorities for applications in the field of headache and migraine research in Fiscal Year 2022. Recognizing the urgent need to increase the study of neurological conditions associated with pain such as headache and migraine, the Fiscal Year 2022 draft budgets from the President, House, and Senate each include proposals to increase funding for pain research within NINDS’ mission. With this NOSI, NINDS wishes to inform the science community of the headache and migraine research opportunities that will present themselves, if funds become available. To be considered for funding through this initiative in Fiscal Year 2022, applications will need to be submitted to corresponding due dates starting in January or February 2022 so they can undergo Scientific Merit and NINDS Advisory Council review for the September 2022 Council round.
For funding consideration, applicants must include “NOT-NS-22-051” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative. Applications deemed nonresponsive to the terms of this notice will not be considered for this initiative.
Although there is still some uncertainty about the final availability of funds, we are excited by the potential to accelerate discovery and therapy development in this critical area, and we hope to encourage investigators to consider submitting applications that can advance our knowledge of the nature of pain and its treatment. Despite the prevalence of headache and migraine and the recent success in treatment opportunities, many questions remain regarding the pathophysiology, progression, and the multitude of endogenous and exogenous factors that influence headache and migraine. The following topic areas are not intended to be comprehensive or exhaustive. Synergistic studies that reach across two or more of these areas are encouraged. Interdisciplinary and multidisciplinary research is especially encouraged, as is research that involves specific cooperation between basic, translational, and clinical scientists.
This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2022.